Natco Pharma Ltd
About
Natco Pharma started in Hyderabad with an investment of ₹3.3 million in 1981 and 20 employees working at a single unit. Today, the company has 8 manufacturing units in Dehradun, Nagarjuna Sagar, Chennai, Guwahati, Visakhapatnam, Kothur, and Mekaguda, and research laboratories spread over 13 states. Natco is focused on the development, manufacturing, and marketing of active pharmaceutical ingredients (APIs) and finished dosage formulations (FDF) in segments like oncology, cardiology, and diabetology. The company has the largest market share of Hepatitis C drugs in India. It has also forayed into the contract manufacturing business and the business of crop health sciences owing to its expertise in organic chemistry. Natco exports its products to more than 50 countries, primarily in the European and American markets.
Featured In Fortune India Ranking
Financial Data 2024
Fortune India Coverage
Financial Data
| PARAMETERS | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (INR Cr) | 4084 44.0% | 2835 37.6% | 2061 -6.5% | 2204 5.1% | 2098 -7.1% | 2259 0.4% | 2251 9.6% | 2053 86.2% | 1102 29.8% | 849 10.1% | 771 11.0% | 695 30.1% | 534 12.8% | 474 4.2% | 455 -0.8% | 458 - |
| Net Operating Income (INR Cr) | 3999 47.72% | 2707 39.20% | 1945 -5.23% | 2052 7.16% | 1915 -8.57% | 2095 -4.13% | 2185 8.15% | 2020 93.82% | 1042 26.30% | 825 11.69% | 739 11.86% | 661 26.12% | 524 13.93% | 460 0.65% | 457 2.96% | 444 32.03% |
| Profit (INR Cr) | 1388 94.1% | 715 320.8% | 170 -61.4% | 441 -4.3% | 461 -28.5% | 644 -7.4% | 696 43.3% | 486 209.4% | 157 16.7% | 135 31.0% | 103 42.9% | 72 20.6% | 60 11.4% | 54 9.8% | 49 10.8% | 44 - |
| Assets (INR Cr) | 6299 22.9% | 5128 7.4% | 4776 6.3% | 4492 7.2% | 4192 6.1% | 3949 20.3% | 3282 73.0% | 1898 33.1% | 1427 21.6% | 1173 19.1% | 985 10.6% | 891 20.2% | 741 27.0% | 583 35.6% | 430 9.7% | 392 - |
| Net Worth (INR Cr) | 5853 20.1% | 4874 14.3% | 4264 3.5% | 4122 9.2% | 3774 8.2% | 3489 13.6% | 3072 86.3% | 1649 27.3% | 1296 53.2% | 846 16.6% | 726 36.1% | 534 12.7% | 474 34.4% | 352 15.3% | 306 18.0% | 259 18.7% |
| Employee Cost (INR Cr) | 525 7.9% | 487 9.4% | 445 7.2% | 415 10.6% | 375 5.4% | 356 9.3% | 326 33.9% | 243 35.3% | 180 31.3% | 137 21.4% | 113 10.3% | 102 27.8% | 80 24.5% | 64 12.3% | 57 5.8% | 54 - |
| Interest Cost (INR Cr) | 19 | 15 | 18 | 13 | 22 | 19 | 15 | 19 | 23 | 32 | 37 | 26 | 23 | 14 | 15 | 15 |
| Cash & Bank Balance (INR Cr) | 953 | 546 | 206 | 284 | 66 | 280 | 184 | 36 | 45 | 13 | 11 | 11 | 37 | 32 | 8 | 29 |
| Total Debt (INR Cr) | 371 | 167 | 416 | 268 | 316 | 386 | 173 | 222 | 113 | 312 | 240 | 338 | 259 | 220 | 120 | 126 |
Key Financial Ratios
| PARAMETERS | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profit As % Of Revenues | 34.0% | 25.2% | 8.3% | 20.0% | 22.0% | 28.5% | 30.9% | 23.7% | 14.3% | 15.9% | 13.3% | 10.3% | 11.2% | 11.3% | 10.7% | 9.6% |
| Profit As % Of Assets | 22.0% | 14.0% | 3.6% | 9.8% | 11.0% | 16.3% | 21.2% | 25.6% | 11.0% | 11.5% | 10.4% | 8.1% | 8.0% | 9.2% | 11.3% | 11.2% |
| Profit As % Of Networth | 23.7% | 14.7% | 4.0% | 10.7% | 12.2% | 18.5% | 22.7% | 29.5% | 12.1% | 15.9% | 14.2% | 13.5% | 12.6% | 15.2% | 15.9% | 17.0% |
| Interest Cost to EBITDA % | 1.1% | 1.6% | 6.7% | 2.2% | 3.7% | 2.4% | 1.7% | 2.7% | 8.6% | 16.2% | 20.4% | 19.0% | 21.1% | 15.7% | 16.1% | 18.7% |
| Debt to Equity Ratio | 0.06 | 0.03 | 0.10 | 0.06 | 0.08 | 0.11 | 0.06 | 0.13 | 0.09 | 0.37 | 0.33 | 0.63 | 0.55 | 0.62 | 0.39 | 0.49 |
| RONW | 25.9% | 15.7% | 3.3% | 11.2% | 12.6% | 19.6% | 29.5% | 32.9% | 14.6% | 18.0% | 15.6% | 14.4% | 14.1% | 15.6% | 16.6% | 18.5% |
| ROCE | 29.6% | 17.7% | 3.8% | 13.7% | 14.5% | 23.4% | 34.9% | 38.8% | 17.5% | 16.6% | 17.8% | 17.2% | 15.5% | 15.7% | 18.6% | 20.2% |